Inozyme Pharma (NASDAQ:INZY) traded higher on Tuesday after Jefferies assumed coverage with a buy rating and a $17 price target, citing three rare disease opportunities for the company’s flagship asset, INZ-701.
Enzyme replacement therapy is currently undergoing clinical trials. Studies on ENPP1 deficiency, calcification, and pseudoexfoliative ectodermal tumor (PXE), a trio of rare disorders caused by deficiency of inorganic pyrophosphate (PPi), a regulator of cell function.
INZ-701, which is designed to boost PPi, could generate $2.5 billion in peak revenue, said Jefferies analyst Murray Rycroft. The experimental treatment could boost PPi to normal levels in these disease areas, the analyst said.
Additionally, Rycroft highlighted upcoming catalysts for INZ-701, including a Phase 1 readout in calcifications and a top-line readout from a pivotal pediatric trial for ENPP1 deficiency scheduled for Q4 and H2 2025, respectively.